71006-38-7

Upstream product

• 7726-11-6 formyl bromide 
• 36187-57-2 1-(4-fluorophenyl)-2-(4-(methylthio)phenyl)ethanone 

Downstream Products

• 97059-74-0 6-(4-Fluoro-phenyl)-5-(4-methylsulfanyl-phenyl)-2,3-dihydro-imidazo[2,1-b]thiazole 
• 177561-24-9 4-(4-fluorophenyl)-5-(4-methylthiophenyl)-2-(thien-2-yl)thiazole 
• 177561-25-0 2-(cyanomethyl)-4-(4-fluorophenyl)-5-(4-methylthiophenyl)-thiazole 
• 130717-63-4 ethyl [4-(4-fluorophenyl)-5-(4-methylthiophenyl)-2-thiazolyl]carboxylate 
• 177561-21-6 2-[3-(4-bromo-phenyl)-propyl]-4-(4-fluoro-phenyl)-5-(4-methylsulfanyl-phenyl)-thiazole 
• 177561-17-0 2-benzyl-4-(4-fluorophenyl)-5-(4-methylthiophenyl)thiazole 
• 177561-32-9 2-((3-Chlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4-methylthiophenyl)-thiazole 
• 177560-23-5 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-[(4-methylsulfonyl)phenyl]thiazole 

Relevant academic research and scientific papers

Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors

A series of novel sulfone substituted 4,5-diarylthiazoles have been synthesized and evaluated for their inhibition of the two isoforms of human cyclooxygenase (COX-1 and COX-2). This series displays exceptionally selective COX-2 inhibition.

Substituted thiazoles for the treatment of inflammation

A class of substituted thiazolyl compounds is described for use in treating inflammation disorders. Compounds are defined by Formula II STR1 wherein R1 is selected from hydrido, alkyl, haloalkyl, cyanoalkyl, alkylamino, aralkyl, arylamino, heteroarylsulfonylalkyl, heteroarylsulfonylhaloalkyl, aralkylamino, aryloxyalkyl, alkoxycarbonyl, aryl optionally substituted at a substitutable position with one or more radicals selected from halo and alkoxy, and heterocyclic optionally substituted at a substitutable position with one or more radicals selected from halo and alkyl; wherein R4 is selected from alkyl and amino; and wherein R5 is selected from aryl and heteroaryl; wherein R5 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkyl and alkoxy; provided R5 is not phenyl at position 4 when R1 is α,α-bis(trifluoromethyl)methanol and R4 is methyl; or a pharmaceutically-acceptable salt thereof.